Rhumbline Advisers Increases Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)

Rhumbline Advisers grew its position in Design Therapeutics, Inc. (NASDAQ:DSGN) by 4.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 52,932 shares of the company’s stock after buying an additional 2,365 shares during the period. Rhumbline Advisers owned approximately 0.09% of Design Therapeutics worth $327,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Paloma Partners Management Co bought a new stake in shares of Design Therapeutics during the third quarter valued at approximately $64,000. China Universal Asset Management Co. Ltd. purchased a new stake in Design Therapeutics during the 4th quarter valued at $74,000. The Manufacturers Life Insurance Company bought a new stake in shares of Design Therapeutics in the 3rd quarter worth $71,000. MetLife Investment Management LLC purchased a new position in shares of Design Therapeutics in the third quarter worth $104,000. Finally, PDT Partners LLC lifted its holdings in shares of Design Therapeutics by 33.1% during the third quarter. PDT Partners LLC now owns 36,099 shares of the company’s stock valued at $194,000 after purchasing an additional 8,972 shares in the last quarter. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Stock Performance

NASDAQ DSGN opened at $4.92 on Monday. Design Therapeutics, Inc. has a one year low of $2.45 and a one year high of $7.77. The stock has a 50-day moving average of $4.89 and a 200 day moving average of $5.36. The company has a market capitalization of $278.58 million, a price-to-earnings ratio of -5.79 and a beta of 1.77.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.